VALIDATED HPLC-UV METHOD FOR SIMULTANEOUS ESTIMATION OF LINAGLIPTIN AND EMPAGLIFLOZIN IN HUMAN PLASMA by Donepudi, Sharmila & Achanta, Suneetha
Original Article 
VALIDATED HPLC-UV METHOD FOR SIMULTANEOUS ESTIMATION OF LINAGLIPTIN AND 
EMPAGLIFLOZIN IN HUMAN PLASMA 
 
SHARMILA DONEPUDIa, SUNEETHA ACHANTAb* 
aDepartment of Pharmaceutical Analysis, V.V. Institute of Pharmaceutical Sciences, Andhra Pradesh 521356, bDepartment of 
Pharmaceutical Analysis, Hindu College of Pharmacy, Andhra Pradesh 522002 
Email: sharmiladonepudi@gmail.com 
Received: 06 Jan 2018, Revised and Accepted: 10 Mar 2018 
ABSTRACT 
Objective: The proposed method aims to develop a simple, rapid, sensitive and validated isocratic reversed-phase high-performance liquid 
chromatography (RP-HPLC) method for the simultaneous estimation of linagliptin and empagliflozin in human plasma. 
Methods: Chromatography was performed on waters 2695 HPLC equipped with a quaternary pump. The separation was carried using discovery 
C18 (250×4.6×5) column, buffer: acetonitrile (68:32) as mobile phase with 1 ml/min flow rate. The analyte detection was monitored at 218 nm. 
Results: Retention time of linagliptin, empagliflozin and internal standard was found at 6.421, 4.696, and 4.074 min respectively. The peaks were 
found to be free of interference. The method is validated over a dynamic linear range of 0.01-10.0 µg/ml for both drugs with a correlation coefficient 
of 0.998. The precision and accuracy of samples of six replicate measurements at lower limit of quantification (LLOQ) level were within the limit. 
The analytes were found to be stable in human plasma at-28 °C for 37 d. 
Conclusion: The stability, sensitivity, specificity and reproducibility of this method make it suitable for the determination of linagliptin and 
empagliflozin in human plasma. 
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Linagliptin (LIN) and empagliflozin (EMP) are used in the treatment of 
type-2 diabetes. The combination was marketed by under the trade 
name Glyxambi. The combination served as an adjuvant to diet and 
exercise to improve glycemia control in adults with type-2 diabetes 
who know to have the cardiovascular disease. General recommended 
dose is with 10 mg of empagliflozin and 5 mg of linagliptin once daily 
in the morning [1-3]. Linagliptin belongs to the class of drugs 
inhibiting the enzyme dipeptidyl-peptidase-4 (DPP-4). Chemically it is 
8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methyl-
quinazolin-2-yl) methyl] purine-2,6-dione. Linagliptin is soluble 
in methanol; sparingly soluble in ethanol; very slightly soluble 
in isopropanol and the solubility in water is<1 mg/ml [4, 5].  
Empagliflozin, a sodium-glucose cotransporter 2, (SGLT2) inhibitor, 
is the newest class of oral hypoglycemic agent [6]. Chemically it is 
(2S,3R,4R,5S.6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl] oxyphenyl] 
methyl] phenyl]-6-(hydroxymethyl) oxane-3,4,5-triol [7]. The 






















Fig. 1: Chemical structure of empagliflozin (a), linagliptin (b) 
 
The literature survey revealed that few methods like Ultra 
Performance Liquid Chromatography (UPLC) [8], High-
Performance Liquid Chromatography (HPLC) [9, 10], Ultraviolet 
Spectroscopy (UV) [11, 12] were reported for estimation of the 
drugs individually orin combination other drugs.  
A bioanalytical also reported for the estimation of empagliflozin 
and linagliptin by Liquid Chromatography-Mass Spectroscopy (LC-
MS) [13] in dosage form etc. The review revealed the estimation of 
this combination was not performed in human plasma. Hence an 
attempt was made to develop a simple, rapid and reproducible RP-
HPLC method for estimation in human plasma for this selected 
combination using telmisartan as an internal standard (IS). The 
developed method was validated as per USFDA [14] guidelines. 
The objective of present bioanalytical technique validation was to 
show that it is reasonable for the indented reason and will be 
useful for the pharmacokinetic studies. 
Experiment 
Reagents and chemicals 
The pure drug samples of linagliptin and empagliflozin were 
purchased from Selleckchem LLC supplied by Pro lab marketing. 
HPLC grade Acetonitrile, HPLC grade Methanol and all other 
chemicals were obtained from Merck chemical division, Mumbai. 
HPLC grade water obtained from Milli-Q water purification system 
was used throughout the study. 
Instrumentation 
Chromatography was performed with waters 2695 HPLC provided 
with a quaternary pump, high-speed autosampler, column oven, 
degasser and and 2996 PDA detector to provide a compact and with 
class Empower-2 software. 
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The separation was achieved by using discovery C18 (250×4.6µ×5 
mm) column with a mobile phase consisting of 0.1% 
orthophosphoric acid and acetonitrile (68:32) with pH adjusted to 
4.5. The separation was monitored for 10 min at 218 nm using 1 
ml/min flow rate. The sample dilution was carried by using water: 
acetonitrile (50:50) ratio as diluent.  
Preparation of internal standard 
The working standard of internal standard was prepared by 
transferring 10 mg of telmisartan to the 10 ml volumetric flask and 
the volume was made by using diluent. From the resulting stock, 
10µg/ml solution was prepared by further dilution.  
Preparation of calibration and quality control solutions 
The stock solutions of empagliflozin and linagliptin were prepared 
individual by dissolving 100 mg of the drug in 10 ml of diluent to 
obtain 10 mg/ml concentration each. The stock solutions were 
further diluted with diluent for spiking in plasma to obtain 
calibration curve standards. The spiking solutions for both analytes 
were prepared by transferring a varied amount to the 10 ml 
volumetric flasks and the volume was made by using diluent. The 
working concentration of both analytes was 0.01 to 10µg/ml. The 
calibration and quality control samples were obtained by spiking 10 
µl of above-prepared solutions of each analyte to 250 µl plasma with 
50 µl of the internal standard. 
Sample preparation and extraction 
The prepared spiking solution of analytes each 10 µl and 50 µl of 
internal standard was spiked into 250 µl of human plasma. To the 
spiked plasma, 2 ml of acetonitrile was added and vortexed for 2 
min. The resulting solutions were centrifuged at 3200 rpm for 3 min. 
The resultant organic layer was used for analysis.  
Methodology 
A thorough and complete method of validation was performed 
following the USFDA guidelines. The method was validated for 
system suitability, autosampler carryover, specificity and screening 
of biological matrix, sensitivity, matrix effect, linearity, precision and 
accuracy, recovery of analyte and internal standard, ruggedness on 
precision accuracy and linearity, reinjection reproducibility and 
stability on day zero, freeze-thaw stability, LT at-28 °C and LT at-80 
°C [15-17]. 
Specificity 
Specificity and screening of biological matrix were assessed by using 
six blank standards and lower limit of quantification (LLOQ) level 
samples. All the samples were checked to determine the extent of 
interference contributed by plasma components with the analyte 
and internal standard. 
Calibration curve 
The Linearity of the method was determined by analysis of standard 
plots associated with an eight-point standard calibration curve. The 
eight concentrations of the studied analytes range from 0.01 to 
10µg/ml including LLOQ. The calibration curve is constructed by 
plotting the peak area ratio of the analytes to the internal standard 
against standard concentrations.  
Accuracy and precision 
Intra-day precision and accuracy were evaluated at lower, middle, 
high and lower limit of quantification quality control samples LQC, 
MQC, HQC and LLOQ in six replicates for both the analytes, while 
inter-day precision and accuracy were assessed for three 
consecutive days by using quality control samples. Mean values 
were obtained for calculated drug concentration over these batches. 
The accuracy and precision were calculated and expressed in terms 
of % mean accuracy and coefficient of variation (% CV), respectively.  
Recovery 
Recovery of the analytes from the extraction procedure was 
performed at LQC, MQC, and HQC levels. It was evaluated by 
comparing peak area of extracted samples (spiked before 
extraction) to the peak area of unextracted samples (quality control 
working solutions spiked in extracted plasma). 
Sensitivity 
Sensitivity is defined as the lowest analyte concentration that can be 
measured with acceptable accuracy and precision (13). Sensitivity 
was done by LLOQ level sample in six replicates to know the lowest 
limit of detection, the % mean accuracy and % coefficient of 
variation was calculated. 
Stability 
Stability studies were performed as zero-hour, freeze-thaw, and long-
term stability at-28 °C and at-80 °C. Day zero, Long-term stability at-28 
°C and at-80 °C stability was carried out by using six replicates of HQC 
and LQC level of samples. The long-term stability of at-28 °C±5 °C was 
carried out by storing samples for 37d. The samples stored at-80 ᵒC are 
thawed and analyzed immediately. The results obtained are compared 
with those obtained by freshly prepared samples. Whereas free-thaw 
stability was assessed by using LQC and HQC level of samples, the % 
mean accuracy and % coefficient of variation was calculated. 
RESULTS AND DISCUSSION 
Method optimization 
To obtain best results for different mobile phase compositions 
containing buffer systems like acetate and phosphate with varied pH 
and organic solvents like methanol and acetonitrile were tried to 
provide adequate sensitivity and selectivity in short separation time. 
The best results were obtained with a mobile phase consisting 0.1% 
phosphoric acid (pH 4.5) and acetonitrile (68:32) with a flow rate of 
1 ml/min. The detection was monitored at 218 nm. With these 
conditions the retention time of linagliptin, empagliflozin and 
telmisartan were obtained at 6.447, 4.716 and 4.079 respectively.  
Method validation 
System suitability and autosampler carry over 
System suitability was performed by using the MQC level sample as 
six homogenous injections. The % coefficient of variation for 
retention time and response was calculated. The results were 
presented in table1. The obtained values are less than 1%, which 
shows the suitability of the system for the analysis of selected 
combination in human plasma.  
Auto sample carryover was done by ULOQ (upper limit of 
quantification) and LLOQ level to ensure that it does not affect the 
accuracy and precision. There was no carryover observed. 
  
Table 1: Statistical analysis of system suitability parameters 
Parameter IS EMP LIN Acceptance 
Retention time (tR) 0.26 0.35 0.47 % RSD ≤ 2 
Area under peak 0.40 0.30 0.51 % RSD ≤ 5 
Resolution (Rs) - 3.32 7.08 Rs>2 
Number of theoretical plates (N) 10086.83 7073.67 10483.67 Increases with the efficiency of the separation. 
Tailing Factor (T) 1.19 1.12 1.21 T ≤ 2  
HETP (cm/plate) 0.0025 0.0035 0.0024 Smaller the value, higher the column efficacy 
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Specificity demonstrates the ability of the method to unambiguously 
assess the analyte of interest in presence of other interfering peaks. 
No endogenous source of interference was observed at the retention 
time of analytes in all six lots of plasma when compared to blank and 
quality control samples. Typical chromatograms corresponding to 
blank and plasma sample spiked with the analyte and internal 
standard are given in Fig.2 and fig. 3 respectively. This shows 
specificity of method towards analytes. 
 
 
Fig. 2: Chromatogram of blank human plasma 
 
 
Fig. 3: Chromatogram of human plasma spiked with empagliflozin, linagliptin and telmisartan 
 
Linearity 
The ratio of peak area of the analyte to internal standard was used 
for the construction of calibration curve. The linearity of both 
analytes was established by eight-point calibration curve, 
concentration ranging from 0.01 to 10µg/ml. The most variable 
regression equation of the calibration curve for empagliflozin and 
linagliptin was y = 0.084x+0.01 and y = 0.0652x+0.0105 
respectively. The linearity of the calibration graph was validated by 
the high value of the correlation coefficient with an average value of 
0.999. The standard curve of empagliflozin and linagliptin are 
presented in fig. 4 and fig. 5. 
 
 
Fig. 4: Standard curve of empagliflozin 
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Fig. 5: Standard curve of linagliptin 
 
Precision and accuracy 
The precision and accuracy of the methods were assessed by 
analyzing six replicates of LLOQ, LQC, MQC and HQC levels. The 
accuracy of the method was determined by calculating % mean 
accuracy and the precision by calculating relative standard 
deviation (RSD). The data of precision and accuracy were 
summarized in table 2. The % mean accuracy of empagliflozin and 
linagliptin ranges from 98.00 to 101.82 and 98.00 to 101.23 
respectively. The results obtained indicate an acceptable precision 
for all concentrations assayed for both intraday and interday 
samples. 
 




mean±SD* % CV % mean recovery mean±SD % CV % mean recovery 
Between-batch 
5.00 5.016±0.2032 4.05 100.32 4.983±0.227 4.56 99.67 
1.00 1.005±0.074 7.32 100.48 0.994±0.065 6.51 99.35 
0.10 0.099±0.008 8.31 99.47 0.100±0.005 4.97 99.91 
0.01 0.010±0.001 8.68 99.35 0.010±0.001 8.14 99.17 
Day 1 (n=6) 
5.00 4.995±0.243 4.87 99.90 5.055±0.231 4.56 101.10 
1.00 0.995±0.075 7.53 99.45 0.980±0.069 6.99 98.03 
0.10 0.100±0.008 8.19 99.67 0.099±0.005 5.32 98.50 
0.01 0.010±0.001 9.67 98.17 0.010±0.001 7.64 98.00 
Day 2 (n=6) 
5.00 4.972±0.197 3.96 99.43 4.951±0.259 5.22 99.03 
1.00 1.018±0.053 5.22 101.82 1.012±0.057 5.65 101.22 
0.10 0.101±0.008 7.85 100.73 0.101±0.006 5.97 100.73 
0.01 0.010±0.001 8.94 100.00 0.010±0.001 9.16 99.50 
Day 3 (n=6) 
5.00 5.082±0.185 3.65 101.64 4.994±0.215 4.35 98.87 
1.00 1.002±0.098 9.78 100.18 0.988±0.075 7.56 98.80 
0.10 0.098±0.010 10.14 98.00 0.101±0.004 4.07 100.50 
0.01 0.010±0.001 8.94 100.00 0.010±0.001 8.94 100.00 
*Each value is represented as mean±SD of 6 observations (n=6), SD-Standard deviation, CV: Coefficient of variation. 
 
Recovery 
Recovery of empagliflozin and linagliptin was determined by 
comparing the mean peak areas of six replicates of three quality 
control samples (HQC, MQC and LQC) with the mean peak areas of 
unextracted quality control samples at the same level.  
The result of recovery study is given in table 3. The results are 
within acceptance limit. The acceptable limit was % CV of recovery 
at each QC level and for IS should be ≤ 15.00 %. The overall mean 
recovery % CV for all QC levels should be ≤ 20.00 %. The results 
obtained indicate the extraction efficiency of the optimized 
method. 
 
Table 3: Extraction recovery data from human plasma 
Analyte Nominal concentration (µg/ml) % Mean Recovery % RSDa 
Empagliflozin 0.1 (LQC) 65.03 0.34 
1.0 (MQC) 66.12 0.12 
5.0 (HQC) 55.16 0.66 
Across mean 62.102 9.72 
Linagliptin 0.1 (LQC) 67.72 1.93 
1.0 (MQC) 62.04 0.37 
5.0 (HQC) 54.39 0.69 
Across mean 61.381 10.90 
Internal standard 10 82.51 0.17 
an=6. % RSD-% Relative Standard Deviation 
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The present method showed good ruggedness when the method was 
performed using different analyst and on the different instrument of 
same make. The results of ruggedness study were found to be within the 
acceptable limit, proving no significant analyst to analyst and instrument 
to instrument variation and hence ruggedness of the method. 
Stability 
The stability of the analytes in human plasma was evaluated by 
analysis six replicates of quality control samples at low and high 
concentration levels at room temperature over 24h(day zero). The 
measured concentrations were compared with that of freshly 
prepared and processed samples. The results obtained indicated 
that the two drugs empagliflozin and linagliptin were stable for at 
least 24hin human plasma when retained at room temperature. 
Freeze-thaw stability of the drugs in plasma samples were studied 
over three freeze-thaw cycles, by thawing at room temperature for 
2–3h and refrozen for 12–24h. On the other hand, results obtained 
for quality control sample at-28 °C for 37 d and at-80 °C indicate the 
stability of analytes in human plasma. The results obtained are 
compiled in table 4. 
 
Table 4: Stability data of empagliflozin and linagliptin in human plasma 
Storage conditions Empagliflozin Lingaliptin 
LQC HQC LQC HQC 
Day zero 
Mean calculated concentration (µg/ml)±SD* 0.10 1±0.008 4.951±0.221 0.098±0.007 5.021±0.111 
%CV 7.80 4.51 7.05 2.02 
% Mean accuracy 101.00 99.03 98.83 100.42 
Freeze-thaw stability (3 cycles) 
Mean calculated concentration (µg/ml)±SD 0.097±0.007 4.975±0.238 0.096±0.005 4.961±0.170 
%CV 7.12 4.78 5.73 3.44 
% Mean accuracy 96.77 99.50 96.29 99.22 
Stability at-28 °C 
Mean calculated concentration (µg/ml)±SD 0.099±0.003 5.012±0.104 0.101±0.008 5.088±0.095 
%CV 2.75 2.09 7.95 1.88 
% Mean accuracy 99.50 100.23 101.00 101.77 
Stability at-80 °C 
Mean calculated concentration (µg/ml)±SD 0.009±0.001 0.097±0.007 0.957±0.072 4.974±0.237 
%CV 7.08 7.12 7.52 4.78 
% Mean accuracy 99.50 100.67 100.52 97.96 
* Each value is represented as mean±SD of 6 observations (n=6), SD-Standard deviation, CV: Coefficient of variation. 
 
CONCLUSION 
The proposed method for estimation of empagliflozin and linagliptin 
binary mixture in human plasma is a simple, accurate and reliable 
method. The single step protein precipitation, the short runtime of 
10 min and isocratic elution makes the method economical and 
suitable for analysis of a large number of samples. The method is 
validated as per the requirement of US-FDA. It can be concluded that 
the method is suitable for routine quantification of empagliflozin 
and linagliptin in human plasma. 
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